Browse News

Found 823 articles

• Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies

  9/27/2023

  Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases, announced the closing of an oversubscribed $175 million Series C financing.

• Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis PatientsApproval triggers $1.5 million milestone payment to Cara

  9/25/2023

  Cara Therapeutics, Inc.  today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd. received manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare for KORSUVA ® IV Injection Syringe for the treatment of pruritus in hemodialysis patients.

• Anokion Announces Nature Biomedical Engineering Publication Further Validating its Immune Tolerance Approach to Treating Celiac Disease and Multiple Sclerosis

  9/19/2023

  Anokion Announces Nature Biomedical Engineering Publication Further Validating its Immune Tolerance Approach to Treating Celiac Disease and Multiple Sclerosis.

• Cataract Surgery with Alcon’s AcrySof IQ Vivity IOLs Demonstrates Sustained High Patient Satisfaction and Reduced Spectacle Dependence

  9/9/2023

  Alcon, the global leader in eye care dedicated to helping people see brilliantly, revealed final data from its Vivity® Registry Study, which monitored real-world patient experiences for up to 12 months post cataract surgery with implantation of either AcrySof® IQ Vivity® or AcrySof® IQ Vivity® Toric presbyopia-correcting intraocular lens.

• Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

  9/5/2023

  Cara Therapeutics, Inc. announced that Christopher Posner, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 9:00 a.m. EDT in New York, NY.

• Cara Therapeutics Reports Second Quarter 2023 Financial Results

  8/7/2023

  Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the second quarter ended June 30, 2023.

• Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors

  8/3/2023

  Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced the appointment of Helen M. Boudreau to its Board of Directors.

• Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

  8/2/2023

  Cara Therapeutics, Inc. today announced that Christopher Posner, President and Chief Executive Officer, will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 8:00 a.m. EDT in Boston, MA.

• Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023

  7/24/2023

  Cara Therapeutics, Inc. today announced the Company will host a conference call and live audio webcast on Monday, August 7, 2023, at 4:30 p.m. ET to report second quarter 2023 financial results and provide a corporate update.

• Cara Therapeutics to Present at the 2023 Jefferies Healthcare Conference

  6/1/2023

  Cara Therapeutics, Inc. announced that Christopher Posner, President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3 p.m. EDT in New York, NY.

• Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

  5/18/2023

  Vifor Fresenius Medical Care Renal Pharma today announced that England’s National Institute for Health and Care Excellence (NICE) has recommended Kapruvia ® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.

• Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

  5/18/2023

  Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. announced that England's National Institute for Health and Care Excellence has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.

• Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting

  5/16/2023

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today six presentations supporting its gene editing, gene therapy and GTx-mAb programs at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting.

• Cara Therapeutics Reports First Quarter 2023 Financial Results

  5/15/2023

  Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced financial results and operational highlights for the first quarter ended March 31, 2023.

• Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights

  5/11/2023

  Homology Medicines, Inc., a genetic medicines company, announced financial results for the first quarter ended March 31, 2023, and highlighted recent accomplishments.

• Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting

  5/3/2023

  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the first presentation of results from IND-enabling studies with HMI-104, the anti-C5 GTx-mAb development candidate for paroxysmal nocturnal hemoglobinuria (PNH).

• Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023

  5/1/2023

  Cara Therapeutics, Inc. today announced the Company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to report first quarter 2023 financial results and provide a corporate update.

• Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference

  4/10/2023

  Cara Therapeutics, Inc. today announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023, at 1:30 p.m. EDT.

• SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full Year 2022

  4/3/2023

  SWK Holdings Corporation, a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided a business update and announced its financial and operating results for the fourth quarter ended December 31, 2022.

• Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting

  3/15/2023

  Homology Medicines, Inc. announced two presentations during the ACMG Annual Clinical Genetics Meeting, which highlight the preclinical data that supported initiation of the Company’s Phase 1 pheEDIT gene editing trial for phenylketonuria and the Phase 1 juMPStart gene therapy trial for Hunter syndrome.